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ABSTRACT 
 
In sheep, contribution of cholinergic system            
to the control of gastrointestinal motility by 
cholecystokinin is unknown. Accordingly, in six 
non-fasted rams chronic experiments were 
conducted and the myoelectrical activity of 
abomasal antrum, duodenum and jejunum was 
recorded before and after injection of atropine (two 
doses), pirenzepine (two doses), hexamethonium or 
atropine plus hexamethonium followed or not by 
injection of three doses of cholecystokinin 
octapeptide or cerulein. In the course of the 
experiments performed, the anticholinergic drugs 
and hormones suppressed spike burst activity both 
in abomasal antrum and small bowel and inhibited 
the migrating myoelectric complex and ‘minute 
rhythm’. When the hormones were injected after 
cholinergic blockade, they induced longer inhibitory 
effects than cholinergic blockade alone. In the small 
bowel, some stimulatory effects were observed as 
well. The higher dose of pirenzepine and remaining 
anticholinergics induced rebound excitation in the 
small bowel, but when followed by cholecystokinin 
peptide administration, no rebound effect was 
denoted. Hexamethonium given alone or in 
combination with atropine followed by chole-
cystokinin peptide caused stronger inhibitory effect 
than that of atropine or pirenzepine. It is concluded 
that cooperation exists between the cholinergic 
system and cholecystokinin in the control of 
gastrointestinal motility in sheep and the role of 
nicotinic mechanisms is greater than that of 
muscarinic mechanisms.  
 
Keywords: Ram; Abomasal antrum; Small 
intestine; Electromyography; Cholecystokinin 
octapeptide; Cerulein; Anticholinergic drug. 
 
1. INTRODUCTION 
  
 Cholecystokinin (CCK) represents the 
meaningful peptide hormone and neuromodulator 
produced by endocrine cells in the gastrointestinal 
mucosa and by neurons in both central and 
peripheral nervous system [1, 2]. The hormone 
modulates motor function both in the stomach and 
small bowel and the character of motility alterations 
mostly depends upon the animal species and 
gastrointestinal segment [3]. CCK, as gastrin, its 
closely related peptide, can inhibit the abomasal 
motility and gastric emptying in the ruminants [4, 
5]. It was reported that in sheep, CCK inhibits the 
arrival of the migrating motor complex (MMC) and 
accelerates small intestinal transit [6, 7]. Cerulein, 
the amphibian CCK, depresses abomasal motility, 
stimulates small intestinal contractions and disrupts 
the MMC in this species [8-13]. Both these peptides 
seem to be able to modulate also the ‘minute 
rhythm’ (MR) in the ovine small bowel [12, 14]. 
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Most of these effects are similar to those observed 
in monogastric species [15-17]. There is also the 
increasing evidence that the nervous system strongly 
contributes to the action of CCK upon the 
gastrointestinal motility and that the action of          
the hormone is largely neuronal, both central             
and peripheral [2, 18]. When CCK was injected 
intracerebroventricularly, it disrupted the MMC 
pattern in the dog and rat [19, 20]. Thus, the 
mechanism of CCK action on gastrointestinal 
motility is composed. In sheep, CCK evoked central 
effect on forestomach motility suggesting that in 
this species CCK can indirectly modulate the 
gastrointestinal motor function [21]. It has also been 
reported that the vagus nerve participates in the 
control of gastrointestinal motility by CCK and the 
central effects are thus possible to occur [6, 22-24]. 
Peripheral administration of CCK does not seem to 
exert central effect directly since CCK probably 
cannot cross the blood-brain barrier [25]. This does 
not exclude the possibility of the involvement of 
peripheral neurons in CCK action upon the 
gastrointestinal motility. The cholinergic system 
could be the first candidate for such cooperation. It 
is well known, also in sheep, that the cholinergic 
system controls effciently the gastrointestinal 
motility and the cholinergic blockade can inhibit 
contractions and disrupt both the MMC and MR 
[26-28]. Several reports indicate that peripheral 
cholinergic system interferes in the actions of CCK 
upon the gastrointestinal motility while the problem 
has not yet been satisfactorily explored [29-31]. 
However, nothing is known about these mechanisms 
in sheep. Thus, the aim of this work was to 
demonstrate the modulatory role of cholinergic 
mechanisms in the action of CCK octapeptide 
(CCK-OP) and cerulein upon the antral, duodenal 
and jejunal motility in conscious rams. It is 
hypothesized that obtained results can embrace the 
question how does CCK cooperate with the 
cholinergic system in the control of ovine 
gastrointestinal motility. 
 
2. MATERIALS AND METHODS 
 
2.1. Animal preparation  
 
 Six healthy, adult, non-fasted rams, each 
weighing 38-44 kg, were used in the chronic 
experiments performed in the study. Animals were 
kept in cages with normal light rhythm. Before and 
after surgery, they were habituated for the 
experiments. Under general and local anaesthesia, 
right lateral laparotomy was performed and five 
platinum bipolar electrodes and one strain gauge 
force transducer (RP Products, Madison) were sewn 
onto the gastrointestinal serosa of each ram. The 
electrode localization was as follows: 1 - the 
abomasal antrum, 4 cm before the pyloric ring,         
2 - the duodenal bulb, 6 cm below the pyloric ring,  
3 - the duodenum, 56 cm distally to the pyloric ring, 
4 - the first jejunal electrode, 256 cm distally to the 
pyloric ring, 5 - the second jejunal electrode, 356 
cm distally from the pyloric ring.  
 The strain gauge force transducers, calibrated 
individually, were attached onto the duodenal serosa 
nearby the third electrode in four of these rams. 
Marked electrode and transducer wires were 
exteriorized over the skin, soldered to the plug in the 
designed order and fixed onto the integument. 
Within 2-3 days following the surgery, animals 
gradually returned to normal feeding and then the 
fodder (good quality hay and the grain mixture) was 
not restricted, except in the course of the 
experiment. The drinking water was restricted only 
during the experiment. The postsurgical recovery 
period lasted at least 10 days and thereafter the        
skin sutures were removed. Other details of the 
experimental model applied in this study were 
reported elsewhere [13, 32]. 
 
2.2. Experimental design 
 
 The total of 252 randomized experiments, 
each lasting 5-8 h, were performed. While the 
experiment was performed in one ram, the second 
ram was also present in the experimental room for 
company. Just before motility recording, the silastic 
cathether was introduced into the left jugular vein of 
each ram for intravenous drug and hormone 
administration. The myoelectric and motor activity 
was recorded throughout the experiments using the 
multichannel electroencephalograph (Reega, Alvar 
Electronic, Paris), also adapted for mechanical 
recordings. Before the experiments, the efficacy of 
the cholinergic blockade was checked in three rams 
with the use of bethanechol preceding atropine or 
pirenzepine administration and DMPP preceding 
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hexamethonium administration.  During the first 
part of the experiment (i.e. before drug and hormone 
administration), the gastrointestinal electromyo-
graphy and motility recordings were conducted.  
The normal motility patterns, namely the MMC and 
the MR were identified. All the MMC phases, 
including phase 2a and 2b, were regularly identified 
during this initial control period according to the 
appropriate criteria [10, 33-35]. 5 ml of 0.15 M 
NaCl was slowly administered intravenously during 
early phase 2b of the MMC. During this part of the 
experiment, at least one full MMC cycle was 
recorded. In the course of the second part of the 
experiment, drugs were given intravenously during 
phase 2b of the next MMC cycle at the doses tested 
previously. The various doses of cholecystokinin 
octapeptide (CCK-OP, Sincalide, Squibb Inst., 
Princeton) and cerulein (Takus, Farmitalia Carlo 
Erba, Milan) were injected after cholinergic 
blockade. Following drug administration, each 
lasting 30 s, the myoelectrical recordings were 
continued until the normal motility was restored, 
especially till the arrival of the normal, non-ectopic 
phase 3 of the MMC. The reference experiments 
(first series) with cholinergic blockade applied alone 
were conducted during which the following 
anticholinergic drugs were injected: atropine sulfate 
(At, Sigma, St. Louis) at the doses 0.02 and 0.1 
mg/kg, each dose given in separate experiment, (2) 
pirenzepine dihydrochloride (Pi, Sigma, St. Louis) 
0.02 and 0.1 mg/kg, each dose given in separate 
experiment, (3) hexamethonium bromide (Hx, 
Sigma, St. Louis) 2.0 mg/kg, (4) At 0.1 in combi-
nation with Hx 2.0 mg/kg given also in separate 
experiments. In the course of the proper experiments 
(second series), one of two CCK peptides was 
administered following cholinergic blockade.          
Each dose of CCK-OP (20, 200 or 2000 ng/kg)          
and cerulein (1, 10 or 100 ng/kg) was preceded by 
administration of the same anticholinergic drug and 
dose during separate experiments. The time lag 
between the smaller doses of Pi or At administration 
and CCK peptide administration was not longer that 
one min. In the case of the remaining types of 
cholinergic blockade, CCK peptides were given 1-2 
min after the anticholinergic drug. At least two days 
overpassed between two consecutive experiments 
while after the experiments with Hx, duration of the 
break lasted at least three days. 
2.3. Analysis of data  
 
 All the recordings were visually analysed in 
order to identify the motility patterns and to evaluate 
the intensity and arrangement of the spike bursts  
and contractions. During the initial part of the 
experiments, i.e. before cholinergic blockade, the 
correctness of motility recordings, mainly the 
occurrence of the normal motility patterns, was 
confirmed. In the abomasal antrum, duration of 
spike burst inhibition was calculated not only when 
complete lack of the spike bursts was present, but 
also comprised the periods in which the inhibition 
reached at least 70% of the maximal spike burst 
amplitude. In the small bowel, duration of the spike 
burst inhibition (regardless of the arrival of 
stimulatory events, i.e. the phase 3 of the MMC, 
premature phase 3, MR and rebound excitation)  
was calculated following the anticholinergic drug 
administration (results treated as the reference 
values) and following CCK peptide administration 
always preceded by cholinergic blockade. Duration 
of MMC disruption was measured from the end of 
anticholinergic drug administration till the arrival of 
the first phase 3 of the MMC at the given recording 
channel (the reference value). The time lags from 
the end of CCK peptide administration (after 
cholinergic blockade) until the onset of the first 
phase 3 of the MMC were measured as well. 
Finally, duration of MR inhibition, from the end of 
the anticholinergic drug administration till the 
arrival of the first MR episode in the given 
recording channel and the time lag from the end of 
CCK peptide injection (administered after cholin-
ergic blockade) till the arrival of the first MR 
episode were measured. After stimulatory effects, 
evoked during the inhibitory period, the spike burst 
inhibition was still present for some time in almost 
all cases. These periods were also taken into account 
during calculations. After termination of the whole 
inhibitory period, the normal gastrointestinal 
motility reappeared. 
 
2.4. Statistical elaboration of data 
 
 All the data were collected, analysed and 
grouped, and the mean values with standard 
deviations (±S.D.) were calculated. All the data 
were rounded and presented as the whole numbers. 
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The normality of data distribution was checked and 
the appropriate comparisons were performed using 
the variance analysis followed by the Student t-test 
for paired values [36]. 
 
2.5. Ethical approval  
 
 Protocol of study and informed consent were 
in compliance with the Helsinki convention and 
were approved by Local Ethics Committee. 
 
3. RESULTS 
 
 During control parts of the experiments, 
saline injections did not evoke any effect upon the 
gastrointestinal motility. 
 Among the anticholinergic substances, Hx 
was the strongest inhibitory drug as to the antral 
myoelectrical activity although the spike burst 
inhibition was complete only in two of six 
experiments and lasted 2-3 min. Partial inhibition 
(less than 70% of the maximal spike burst 
amplitude) was approximately 2-3 times longer in 
this region than the periods of complete inhibition. 
Similar situation was observed following the 
combined cholinergic blockade, i.e. At plus Hx 
(At+Hx) administration (Table 1). After the smallest 
dose of CCK-OP administration preceded by Hx or 
by At + Hx, duration of the inhibitiory periods was 
slightly but significantly shorter than that after the 
relevant anticholinergic drug dose given alone. 
When the highest doses of CCK-OP and cerulein 
were applied after cholinergic blockade, the 
inhibitory periods were significantly longer as 
compared with the higher doses of At or Pi and with 
Hx or At + Hx administration (Figure 1). Cerulein 
induced more pronounced effect than CCK-OP 
(Table 1). Following the higher dose of At, cerulein 
exerted dose-dependent inhibitory effect upon the 
antral spike burst amplitude. The inhibitory effect 
evoked by the maximal doses of both CCK peptides, 
given after Hx, lasted longer than in response to Hx 
applied alone. After Pi and At, the effect of CCK 
peptide was slightly shorter than that after Hx 
(Table 1). 
 
 
 
Figure 1. The effects of muscarinic blockade followed by 
cerulein administration upon the myoelectrical and motor 
activity of ovine abomasal antrum, duodenum and 
jejunum. Upper panel: administration of atropine at the 
dose 0.1 mg/kg (marked). Middle panel: continued 
recording, administration of cerulein at the dose 100 
ng/kg (marked). Lower panel: next two minutes 
following cerulein administration. Note partial inhibition 
of the antral spike bursts after atropine and complete 
inhibition after cerulein administration. Complete 
inhibition of the intestinal motility in response to 
cholinergic blockade followed by cerulein administration 
with lack of the rebound effect, except the presence of 
single spike burst in the duodenum resembling the 
residual ‘minute rhythm’ during cerulein administration 
is also visible. 
Explanations: t - time in seconds; A - electromyogra-
phical recording from the abomasal antrum; B - the 
duodenal bulb, D - the duodenum; J1 - proximal jejunum; 
J2 - recording from the the second jejunal electrode;       
T - mechanical recording from the duodenal strain gauge 
force transducer; C - electrode and transducer calibration, 
100 μV and 5g, respectively; ┘(the bent bar) - termi-
nation of drug or hormone administration. Other 
explanations are as in the chapter Materials and Methods. 
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Table 1. Duration of the spike burst inhibition in the abomasal antrum by the cholinergic blockade applied alone and by 
the cholinergic blockade followed by cholecystokinin peptide administration in rams. 
 
Atropine Pirenzepine 
Hexam. 2.0 Atropine 0.1 
+ Hexam. 2.0 0.02 0.1 0.02 0.1 
No CCK 
peptide 
Mean 
±S.D. 
0 
0 
1.0 
0.0 
0 
0 
0 
0 
4 
2 
5 
2 
CCK-OP 
20.0 
Mean 
±S.D. 
0 
0 
0c 
0 
0 
0 
0 
0 
1a 
0 
2a 
1 
CCK+OP 
200.0 
Mean 
±S.D. 
0 
0 
0c 
0 
0 
0 
0 
0 
3y 
1 
4 
2 
CCK+OP 
2000.0 
Mean 
±S.D. 
2cz 
1 
2az 
1 
4cz 
1 
6cz 
3 
8az 
2 
9y 
4 
Cerulein 
1.0 
Mean 
±S.D. 
0 
0 
0c 
0 
0 
0 
1b 
0 
2 
1 
4x 
1 
Cerulein 
10.0 
Mean 
±S.D. 
0 
0 
1c 
0 
0 
0 
0 
0 
3 
1 
5 
2 
Cerulein 
100.0 
Mean 
±S.D. 
0 
0 
5cz 
2 
4cz 
1 
7cz 
3 
11cz 
5 
10x 
4 
Explanations: doses of the anticholinergic drugs expressed in mg/kg, doses of CCK peptides expressed in ng/kg. Statistical 
significances: n=6; aP<0.05, bP<0.01, c P<0.001 vs. reference value (no CCK peptide administration); xP<0.05, yP<0.01, 
zP<0.001 vs. the relevant value obtained in response to the lowest dose of CCK peptide. Other explanations as in the 
chapter Material and methods.          
 
 
Table 2. Partial excitatory events observed during inhibitory periods evoked by the cholinergic blockade applied alone and  
by the cholinergic blockade followed by cholecystokinin peptide administration in rams. 
 
 
 
 
Duodenal bulb Duodenum Jejunum 1 Jejunum 2 
At 
l   h 
Pi 
l   h Hx 
At+ 
Hx 
At 
l   h 
Pi 
l   h Hx 
At+ 
Hx 
At 
l   h 
Pi 
l   h Hx 
At+ 
Hx 
At 
l   h 
Pi 
l   h Hx 
At+ 
Hx 
No 
CCK 0 0 0 0 4 3 1 3 2 2 6 3 2 4 4 5 1 2 0 2 4 4 0 2 
OP 
20.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 2 0 0 0 
OP 
200.0 1 0 0 0 0 0 3 0 3 0 1 1 0 1 5 1 1 0 0 0 5 1 0 0 
OP 
2000.0 5 1 0 1 0 0 4 1 4 6 0 2 2 3 1 1 0 1 0 0 0 4 0 2 
Cer 
1.0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 1 1 0 0 
Cer 
10.0 2 0 1 0 0 0 3 2 2 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 
Cer 
100.0 6 0 3 3 0 0 5 4 5 4 0 1 4 0 5 6 3 1 3 0 0 5 0 0 
Values represent numbers of the experiments in which the excitatory event arrived. The excitatory events comprised three 
types of episodes. The premature phase 3 was observed in response to Pi administration at the lower dose. The rebound 
excitation was seen in the experiments with remaining types of the cholinergic blockade and after the lower dose of Pi 
followed by CCK peptide administration. The presence of single spike bursts was denoted once after the moderate dose of 
CCK peptide or often 2-3 times following its highest dose. l. - lower dose (0.02 mg/kg), h. higher dose (0.1 mg/kg);          
OP - cholecystokinin octateptide; Cer - cerulein. Other explanations as in Table 1.         
 
36 | Romański   Cholinergic system and CCK in ovine digestive motility 
European Journal of Biological Research 2017; 7 (1): 31-49 
 
In the small intestine, unlike in antrum, 
administration of the anticholinergic drugs follo-
wed or not by CCK peptides, induced various 
stimulatory effects that arrived during the inhibitory 
periods. The premature phase 3 was evoked in the 
most cases only by Pi given alone at the lower dose 
(as shown in Table 2). Administration of At, the 
higher dose of Pi, Hx and At + Hx, not followed by 
CCK peptide, evoked clear rebound excitation 
exhibiting stationary character. When the animals 
were treated by the lower dose of Pi and then by 
CCK peptide, no premature phase 3 arrived and 
instead, the rebound excitation was observed, but 
not in all the animals studied (Figure 2). When  
CCK peptide followed the administration of At, the 
higher dose of Pi, Hx and At + Hx, no rebound 
excitation was observed although the spike burst 
inhibition was incomplete (Figure 3). Following      
the cholinergic blockade, the arrival of usually one 
or two separate stronger spike bursts was often 
observed in the duodenum during or just after CCK 
peptide injection at the moderate or high dose 
(Table 2, Figure 1). These single spike bursts resem-
bled the MR-forming spike bursts. Sometimes, 
following the moderate dose of the peptide, more 
than one isolated spike burst was observed. These 
effects are also presented in Table 2. 
 Duration of the spike burst inhibition was 
different in the various small intestinal segments. 
When the cholinergic blockade was applied, the 
spike burst inhibition (calculated including periods 
when the excitatory effects occurred during the 
inhibitory response, namely the premature phase    
3, rebound excitation or the isolated spike burst) 
lasted longer in the duodeno-jejunum than in              
the duodenal bulb (Table 3A, B). Among the 
anticholinergic drugs, Hx exerted the strongest 
inhibitory effect, especially in the jejunum, where 
the Hx-evoked rebound excitation was usually 
absent (Figure 4). At induced rebound excitation 
mostly in the duodeno-jejunum and rather not               
in the duodenal bulb. When CCK peptides were 
given after cholinergic blockade, they often  exerted 
significant, dose-related effect. Following the 
highest dose of both CCK peptides, the inhibitory 
period lasted much longer than after both lower 
doses. The effect of cerulein was often more 
pronounced that the relevant effect of CCK-OP. It 
was seen mostly in the jejunum. Introduction of           
the lower dose of At followed by cerulein, inhibited 
the spike bursts for the period longer than in the 
experiments in which the same dose of cerulein 
injection was preceded by the higher dose of At 
(Table 3A, B). Similar observation concerned also 
Pi. In all the regions examined, administration of  
Hx or At + Hx combined with both CCK peptides 
evoked significantly longer inhibitory effects than 
those of At and Pi when injected before CCK 
peptide, regardless of their doses (Table 3A,B, see 
also Figure 5). Cerulein, given at the lowest dose 
and preceded by the both doses of Pi, produced 
significantly shorter inhibitory response in the 
duodenum than Pi given alone. CCK-OP, used at       
the lowest dose and preceded by the lower dose              
of Pi, Hx or by higher dose of At, inhibited spike 
burst activity in the jejunum for significantly     
shorter time than the relevant anticholinergic             
drug given alone (Table 3A, B). 
 
 
Figure 2. The effects of muscarinic blockade followed by 
cholecystokinin octapeptide (CCK-OP) administration 
upon the myoelectrical activity of ovine abomasal 
antrum, duodenum and jejunum after muscarinic 
blockade. Upper panel: administration of pirenzepine (Pi) 
at the dose 0.02 mg/kg (left bar) followed by CCK-OP at 
the dose 200 ng/kg (right bar). Lower panel: continued 
recording after OP-CCK administration. Note the 
stronger inhibitory effect on antral spike burst after OP-
CCK than after Pi. Pi did not inhibit the jejunal 
myoelectric activity and OP-CCK inhibited it in part.  
Symbol explanations as in Figure 1. 
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Table 3A. Duration of the spike burst inhibition in the duodenal bulb and the duodenum in response to the cholinergic 
blockade applied alone and to the cholinergic blockade followed by cholecystokinin peptide administration in rams. 
Explanations as in Table 1. 
 
          
Table 3B. Duration of the spike burst inhibition in the upper and more distal jejunum by the cholinergic blockade applied 
alone and by the cholinergic blockade followed by cholecystokinin peptide administration in rams. 
 J e j u n u m    1 J e j u n u m    2 
 
Atropine Pirenzep. Hx At 0.1 + 
Hx 2.0 
Atropine Pirenzep. Hx At 0.1 + 
Hx 2.0 0.02 0.1 0.02 0.1 2.0 0.02 0.1 0.02 0.1 2.0 
No CCK 
peptide 
Mean 
±S.D. 
8 
3 
14 
7 
7 
2 
9 
3 
12 
5 
13 
6 
3 
1 
15 
7 
3 
1 
6 
3 
16 
6 
12 
6 
CCK-OP 
20.0 
Mean 
±S.D. 
6 
1 
12 
5 
2a 
1 
11 
4 
7 
3 
24 
7 
12b 
4 
8 
2 
2 
1 
5 
2 
6a 
2 
32c 
8 
CCK-OP 
200.0 
Mean 
±S.D. 
9x 
2 
20 
8 
14az 
5 
13 
5 
8 
3 
38c 
8 
17c 
6 
19z 
4 
15cz 
6 
7 
2 
14 
7 
41c 
12 
CCK OP 
2000.0 
Mean 
±S.D. 
18ax 
5 
26 
11 
23cz 
9 
22bx 
6 
24az 
7 
57cz 
18 
14a 
8 
25z 
6 
23cz 
8 
12x 
5 
16x 
6 
54c 
16 
Cerulein 
1.0 
Mean 
±S.D. 
11 
5 
12 
5 
6 
2 
7 
2 
53c 
16 
21 
8 
18c 
6 
14 
6 
9a 
3 
3 
1 
30 
12 
38c 
13 
Cerulein 
10.0 
Mean 
±S.D. 
17a 
6 
7 
2 
11 
4 
5 
2 
78c 
24 
35cx 
6 
25c 
11 
6ax 
2 
14c 
5 
6 
3 
45c 
16 
52c 
19 
Cerulein 
100.0 
Mean 
±S.D. 
24bx 
9 
8 
3 
18bz 
5 
6 
2 
96c 
31 
49cz 
9 
28c 
11 
7 
3 
36cz 
11 
8x 
3 
63cx 
21 
86cz 
24 
Explanations as in Table 1.        
 
 
 Duration of inhibition of phase 3 of the MMC 
was often long and dependent upon the intestinal 
segment examined. In the most distal recording 
channel (jejunum 2), these periods were usually 
shorter than in the proximal sites since the first 
phase 3 of the MMC, which arrived after cholin-
ergic blockade applied alone and also after the 
combination of anticholinergic drugs with CCK 
peptides, was ectopic. It was started most often just 
from this distal region (Table 4A, B). Duration of 
 D u o d e n a l    b u l b D u o d e n u m 
 
Atropine Pirenzep. Hx At 0.1 + 
Hx 2.0 
Atropine Pirenzep. Hx At 0.1 + 
Hx 2.0 0.02 0.1 0.02 0.1 2.0 0.02 0.1 0.02 0.1 2.0 
No CCK 
peptide 
Mean 
±S.D. 
4 
1 
3 
1 
2 
1 
4 
2 
7 
2 
7 
3 
6 
3 
10 
4 
14 
6 
15 
5 
11 
4 
12 
6 
CCK-OP 
20.0 
Mean 
±S.D. 
10b 
2 
17c 
7 
6a 
2 
7 
3 
16a 
7 
29c 
7 
8 
4 
19 
8 
15 
6 
12 
4 
9 
4 
26a 
7 
CCK OP 
200.0 
Mean 
±S.D. 
16cx 
4 
24c 
9 
16cz 
3 
5 
2 
33cx 
11 
42c 
9 
13 
5 
25a 
10 
24 
9 
8 
3 
26ax 
11 
61cz 
19 
CCK OP 
2000.0 
Mean 
±S.D. 
 
13b 
6 
39cx 
14 
19cz 
5 
18cx 
7 
48cz 
19 
61cz 
15 
12 
6 
32c 
11 
17 
8 
19 
5 
34cz 
13 
93cz 
27 
Cerulein 
1.0 
Mean 
±S.D. 
11a 
5 
8a 
3 
5a 
2 
12a 
5 
54c 
16 
33c 
12 
12 
4 
9 
3 
2c 
1 
5b 
2 
32c 
11 
28b 
7 
Cerulein 
10.0 
Mean 
±S.D. 
19c 
9 
11b 
4 
17cy 
7 
46cz 
14 
60c 
17 
52c 
11 
14a 
5 
13 
5 
12z 
5 
9 
4 
35c 
14 
46cx 
10 
Cerulein 
100.0 
Mean 
±S.D. 
23cz 
7 
28cz 
12 
21cz 
6 
16b 
7 
66c 
20 
58c 
17 
18b 
6 
25ax 
11 
18z 
7 
14y 
4 
55c 
19 
49cx 
12 
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phase 3 inhibition was longer after Hx or after At + 
Hx administration than after At or Pi. Despite of the 
arrival of premature phase 3 following the lower 
dose of Pi, no inhibitory effect on the regular phase 
3 was denoted and the arrived regular phase 3 of the 
MMC was not ectopic. The premature phase 3 was 
often ectopic and abortive. When At or Pi were 
injected, duration of the subsequent phase 3 
inhibitory periods was related to the drug dose. 
When CCK peptide administration followed the 
cholinergic blockade, the time lags, measured from 
CCK administration until the appearance of the 
regular ectopic phase 3, were significantly longer 
than after cholinergic blockade alone (Table 4A, B). 
Following the highest doses of CCK peptides, these 
periods were relatively very long. In the most 
experiments, the effect of CCK-OP administration 
was more pronounced than the effect of relevant 
dose of cerulein, at least in the duodenum and upper 
jejunum (Table 4A, B). 
 
 
 
Figure 3. The effects of muscarinic blockade followed by 
cholecystokinin octapeptide (CCK-OP) administration 
upon the myoelectrical activity of ovine abomasal 
antrum, duodenum and jejunum.  
Upper panel: administration of pirenzepine (Pi) at the 
dose 0.1 mg/kg (marked). Lower panel: continued 
recording and administration of CCK-OP at the dose 200 
ng/kg (marked). Note the inhibition of intestinal motility 
by pirenzepine and lack of rebound effect. CCK-OP 
exerted slight stimulatory effect in the upper jejunum. No 
clear inhibition of antral myoelectrical activity is also 
visible. Symbol explanations as in Figure 1. 
 
Figure 4. The effects of nicotinic blockade followed by 
cerulein administration upon the myoelectrical and motor 
activities in the ovine abomasal antrum, duodenum and 
jejunum. Upper panel: adninistration of hexamethonium 
(Hx) at the dose 2.0 mg/kg (marked). Lower panel: 
continued recording and administration of cerulein at the 
dose 100 ng/kg (marked). Note the partial inhibition of 
antral spike bursts by Hx and complete inhibition by 
cerulein. The electrical and mechanical activity of the 
small intestine is also inhibited by both of these drugs. 
Symbol explanations as in Figure 1. 
 
 
 The time lags between cholinergic blockade 
and arrival of the first MR episode were usually 
shorter than phase 3 disruption periods in all the 
small intestinal segments examined (Tables 4A, B, 
5A, B). In the most experiments, duration of MR 
inhibition was longer following Hx or At + Hx 
administration than that after At or Pi (Table 5 A, 
B). Following At injection, this effect was dose-
related in all segments examined while after Pi it 
was rather dose-independent and relatively short. 
Duration of MR inhibition following CCK-OP and 
cerulein application after cholinergic blockade 
exhibited dose-related character, especially in the 
jejunum. Administration of both CCK peptides, at 
least at two highest doses, often delayed MR arrival 
for significantly longer periods than the cholinergic 
blockade applied alone. These periods were the 
longest when Hx or At+Hx was followed by CCK 
peptide administration, especially at its highest dose.  
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Table 4A. Duration of inhibition of the phase 3 of the migrating myoelectric complex in the duodenal bulb and the 
duodenum by the cholinergic blockade applied alone and by the cholinergic blockade followed by cholecystokinin peptide 
administration in rams. 
 D u o d e n a l    b u l b D u o d e n u m 
 
Atropine Pirenzep. Hx At 0.1 
+ 
Hx 2.0 
Atropine Pirenzep. Hx At 0.1 
+ 
Hx 2.0 0.02 0.1 0.02 0.1 2.0 0.02 0.1 0.02 0.1 2.0 
No CCK 
peptide 
Mean 
±S.D. 
26 
11 
62 
18 
29 
8 
34 
14 
73 
22 
64 
19 
17 
8 
63 
19 
21 
9 
67 
22 
56 
11 
66 
17 
CCK-OP 
20.0 
Mean 
±S.D. 
49a 
10 
76 
18 
45 
17 
31 
10 
83 
24 
54 
14 
42c 
6 
64 
21 
46a 
15 
75 
24 
63 
21 
52 
15 
CCK-OP 
200.0 
Mean 
±S.D. 
68c 
21 
61 
21 
71c 
23 
117cz 
38 
131cy 
21 
87 
21 
58c 
20 
71 
22 
61c 
20 
119 
39 
116c 
38 
89z 
17 
CCK-OP 
2000.0 
Mean 
±S.D. 
96cz 
27 
116c 
28 
74c 
14 
124cz 
35 
186cz 
45 
158cz 
39 
104cz 
32 
117cx 
30 
83c 
37 
178cz 
41 
166cz 
39 
155cz 
37 
Cerulein 
1.0 
Mean 
±S.D. 
47 
12 
56 
17 
41 
18 
62a 
14 
78 
16 
66 
17 
34 
16 
58 
17 
43 
16 
94 
19 
81 
19 
59 
16 
Cerulein 
10.0 
Mean 
±S.D. 
56c 
11 
70 
21 
79c 
24 
68c 
12 
148cz 
35 
121cy 
34 
65c 
22 
104cx 
29 
65c 
18 
88 
23 
146cz 
34 
120cz 
32 
Cerulein 
100.0 
Mean 
±S.D. 
87cz 
20 
98x 
24 
86cx 
26 
73c 
19 
197cz 
46 
176cz 
48 
85cz 
18 
107cz 
27 
79c 
25 
74 
21 
198cz 
48 
174cx 
47 
Explanations as in Table 1.          
 
 
Table 4B. Duration of inhibition of the phase 3 of the migrating myoelectric complex in the upper and more distal jejunum 
by the cholinergic blockade applied alone and by the cholinergic blockade followed by cholecystokinin peptide 
administration in rams. 
 J e j u n u m    1 J e j u n u m    2 
 
Atropine Pirenzep. Hx At 0.1 
+ 
Hx 2.0 
Atropine Pirenzep. Hx At 0.1 
+ 
Hx 2.0 0.02 0.1 0.02 0.1 2.0 0.02 0.1 0.02 0.1 2.0 
No CCK 
peptide 
Mean 
±S.D. 
18 
4 
38 
16 
19 
7 
34 
13 
45 
9 
37 
14 
17 
5 
37 
15 
20 
5 
35 
13 
35 
12 
38 
16 
CCK-OP 
20.0 
Mean 
±S.D. 
33b 
8 
49 
22 
48a 
21 
47 
13 
38 
17 
53 
12 
28 
11 
43 
18 
27 
11 
23 
8 
45 
14 
37 
12 
CCK-OP 
200.0 
Mean 
±S.D. 
57c 
18 
73 
25 
52c 
16 
120cz 
36 
62 
26 
76c 
19 
39a 
15 
54 
24 
22 
7 
34 
11 
59 
18 
49 
11 
CCK-OP 
2000.0 
Mean 
±S.D. 
102cz 
30 
86c 
24 
67c 
28 
134cz 
35 
139cz 
28 
153cz 
38 
87cz 
21 
58 
16 
66cz 
20 
67az 
17 
118cz 
32 
76cz 
13 
Cerulein 
1.0 
Mean 
±S.D. 
28 
12 
42 
11 
54c 
19 
29 
12 
62 
24 
60 
14 
21 
8 
41 
10 
18 
4 
27 
11 
43 
12 
31 
9 
Cerulein 
10.0 
Mean 
±S.D. 
54c 
16 
48 
16 
58c 
18 
45 
21 
111c 
44 
122cz 
33 
39c 
11 
47 
14 
29 
10 
39 
17 
76cx 
21 
78bz 
20 
Cerulein 
100.0 
Mean 
±S.D. 
69cz 
19 
52 
14 
61c 
17 
48 
19 
176cz 
51 
156cz 
54 
53cz 
17 
53 
13 
38az 
11 
54 
21 
109cz 
26 
135cz 
33 
Explanations as in Table 1.          
 
 
 These effects were most pronounced in more 
distal jejunum (Table 5A, B). In the most 
experiments, initial administration of lower doses of 
At and Pi potentiated the MR inhibition by CCK 
peptide even more than pretreatment with their 
higher doses. When cerulein administration at the 
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lowest dose was preceded by the higher dose of At, 
MR inhibition was significantly shortened as 
compared with the experiments with At alone 
(Table 5A, B). 
 
 
Table 5A. Duration of the ‘minute rhythm’ inhibition in the duodenal bulb and the duodenum by the cholinergic blockade 
applied alone and by the cholinergic blockade followed by cholecystokinin peptide administration in rams. 
 D u o d e n a l    b u l b D u o d e n u m 
 
Atropine Pirenzep. Hx At 0.1 
+ 
Hx 2.0 
Atropine Pirenzep. Hx At 0.1 
+ 
Hx 2.0 0.02 0.1 0.02 0.1 2.0 0.02 0.1 0.02 0.1 2.0 
No CCK 
peptide 
Mean 
±S.D. 
14 
5 
28 
7 
8 
3 
7 
3 
41 
10 
38 
11 
8 
3 
23 
10 
9 
4 
11 
5 
45 
11 
46 
12 
CCK-OP 
20.0 
Mean 
±S.D. 
15 
4 
31 
9 
15 
5 
9 
3 
52 
18 
44 
13 
11 
4 
32 
10 
16 
5 
12 
4 
45 
21 
38 
11 
CCK-OP 
200.0 
Mean 
±S.D. 
39bz 
16 
48 
19 
17a 
6 
12 
4 
97cz 
18 
46 
17 
28cz 
8 
46 
17 
18 
7 
13 
4 
32 
8 
64 
18 
CCK+OP 
2000.0 
Mean 
±S.D. 
58cz 
18 
79cz 
22 
33cy 
9 
22ax 
10 
146cz 
38 
68a 
17 
42cz 
14 
80cz 
23 
26b 
9 
22ax 
6 
96cx 
31 
97cz 
24 
Cerulein 
1.0 
Mean 
±S.D. 
18 
7 
8c 
2 
9 
3 
6 
2 
56 
12 
52 
16 
24c 
4 
8a 
3 
17a 
4 
14 
6 
36 
9 
49 
17 
Cerulein 
10.0 
Mean 
±S.D. 
48cz 
12 
12c 
4 
16 
6 
15ay 
4 
63 
19 
76b 
21 
18a 
6 
12 
5 
26c 
7 
18 
8 
32 
12 
56 
18 
Cerulein 
100.0 
Mean 
±S.D. 
10 
4 
22y 
10 
7 
3 
24cz 
7 
68a 
16 
64 
19 
9z 
2 
23y 
8 
11x 
3 
25a 
8 
57 
18 
55 
21 
Explanations as in Table 1.        
 
 
Table 5B. Duration of the ‘minute rhythm’ inhibition in the upper and more distal jejunum by the cholinergic blockade 
applied alone and by the cholinergic blockade followed by cholecystokinin peptide administration in rams. 
 J e j u n u m    1 J e j u n u m    2 
 
Atropine Pirenzep. Hx At 0.1 
+ 
Hx 2.0 
Atropine Pirenzep. Hx 
2.0 
At 0.1 
+ 
Hx 2.0 0.02 0.1 0.02 0.1 2.0 0.02 0.1 0.02 0.1 
No CCK 
peptide 
Mean 
±S.D. 
9 
3 
19 
6 
16 
5 
10 
4 
42 
14 
45 
12 
13 
5 
23 
11 
14 
7 
16 
7 
54 
10 
36 
11 
CCK-OP 
20.0 
Mean 
±S.D. 
10 
3 
31 
10 
16 
6 
12 
3 
33 
11 
26 
7 
34c 
6 
54a 
16 
24 
9 
17 
6 
44 
18 
43 
11 
CCK-OP 
200.0 
Mean 
±S.D. 
29cz 
11 
47b 
18 
19 
6 
24cz 
4 
48 
18 
42 
14 
29b 
8 
66c 
20 
29 
12 
30ax 
7 
66 
15 
66 
21 
CCK-OP 
2000.0 
Mean 
±S.D. 
43cz 
15 
80cz 
21 
25 
8 
46cz 
12 
96cz 
24 
62z 
17 
47c 
16 
84c 
25 
26 
8 
45cz 
13 
105ax 
41 
106cz 
32 
Cerulein 
1.0 
Mean 
±S.D. 
33c 
12 
9a 
3 
11 
3 
9 
3 
34 
9 
28 
9 
38c 
10 
10 
3 
16 
5 
22 
8 
54 
17 
52 
12 
Cerulein 
10.0 
Mean 
±S.D. 
30c 
11 
13 
5 
25z 
6 
18x 
6 
61x 
19 
61z 
21 
27a 
9 
15 
5 
36a 
14 
39b 
13 
84a 
21 
87cx 
22 
Cerulein 
100.0 
Mean 
±S.D. 
26c 
8 
24y 
8 
46cz 
14 
25ay 
9 
86cz 
14 
99cz 
28 
31a 
11 
24y 
7 
42by 
18 
38b 
12 
119cz 
26 
106cz 
33 
Explanations as in Table 1.         
 
 
41 | Romański   Cholinergic system and CCK in ovine digestive motility 
European Journal of Biological Research 2017; 7 (1): 31-49 
 
 
Figure 5. The effects of combined muscarinic-nicotinic 
blockade followed by cholecystokinin octapeptide (CCK-
OP) administration upon the myoelectrical activity of the 
ovine abomasal antrum, duodenum and jejunum.  
Upper panel: adminstration of atropine at the dose 0.1 
mg/kg (left bar) and hexamethonium at the dose 2.0 
mg/kg (right bar). Lower panel: administration of CCK-
OP at the dose 2000 ng/kg (marked). Note the partial 
inhibition of antral spike burst by anticholinergic drugs 
and complete inhibition by CCK-OP. The inhibition of 
the intestinal myoelectrical activity is seen both after 
cholinergic blockade and CCK-OP administration. 
Symbol explanations as in Figure 1. 
 
 
4. DISCUSSION    
 
 The results indicate that CCK profoundly 
contributes to the control of motility of the ovine 
abomasal antrum and upper small bowel, and its 
effects can be efficiently mediated by the 
cholinergic system. In the abomasal antrum, 
inhibitory effects were evoked primarily by 
cholinergic blockade. In sheep, the influence of At 
and other anticholinergic drugs on the antral spike 
bursts and contractions is limited as it was observed 
in the present and previous study [35]. Similar 
observations were reported in man and dog [30, 37]. 
Wong and McLeay [38], in the in vitro study on 
ovine antral smooth muscle preparations, did not 
observe any influences of At or Hx upon the 
spontaneous contractions. As it was found in the 
present study, when the anticholinergic drug 
administration was followed by CCK injection, 
inhibition of antral spike bursts was much longer 
than after cholinergic blockade applied without 
subsequent CCK administration. These effects were 
also more distinct than the effects of both CCK 
peptides administered without cholinergic blockade 
although they were also inhibitory [9, 39]. Thus it is 
clear that in ovine abomasal antrum, CCK exerts 
inhibitory effect what was observed also by others 
[7]. Antral response to CCK is not the same in sheep 
and dog in which it can be stimulatory [29, 40]. 
Other studies confirmed further the presence of 
marked species differences. When CCK was given 
intraarterially in vivo or during in vitro studies with 
the canine antral muscle, it also exerted stimulatory 
effect [37, 41]. In man, the reported effects of CCK 
on antral motility are controversial. Its stimulatory 
effect in vitro was confirmed in vivo by the 
inhibitory action of loxiglumide, the CCK receptor 
antagonist, although the suppressive action of CCK 
on human antral motility was observed as well [30, 
42, 43]. In rats, stimulatory, inhibitory or the lack of 
the effect was denoted [44, 45]. In the guinea pig, 
stimulatory action of CCK seems to predominate 
although the presence of dual effect was also 
described [46-48]. The effect of CCK on antral 
motility is, thus, distinct in sheep what suggests that 
the mechanism of CCK action might be somehow 
different from that observed in other species. 
Moreover, the obtained results show that in sheep 
CCK amplified inhibitory effect evoked by the 
cholinergic blockade. This effect of CCK was dose-
dependent, at least in part, and it also seems to be 
additive to the effect induced by cholinergic 
blockade. The existence of cooperation of CCK  
with acetylcholine has been described [1], but it 
seems improbable during the efficient cholinergic 
blockade. This cooperation may concern rather 
stimulatory than inhibitory action of CCK. The 
effect of CCK on the ovine gastrointestinal motility 
can be dual [13, 49], thus it is possible that in the 
present study the anticholinergic drugs hampered 
exclusively the stimulatory component of CCK 
action prolonging the inhibitory effect. At least three 
pathways of CCK action on antral motility under 
cholinergic blockade can be considered, however. 
CCK might be able to evoke the inhibitory effect 
rather independently of the cholinergic system and 
this effect could be local and direct on the smooth 
muscle that represents first possibility.  
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Figure 6. Proposed mechanisms of CCK actions on gastrointestinal motility. Other explanations see text.  
 
 
Figure 7. Proposed neuronal CCK actions on gastrointestinal motility during various types of cholinergic blockade. Other 
explanations see the text. 
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 CCK can also act as a neuromodulator         
what represents second possibility [28, 50]. Third 
possibility occurs when the action of CCK could be 
amplified by inhibitory effect of such hormone as 
somatostatin released by CCK from the ovine 
antrum [51]. Some possible mechanisms of CCK 
action on gastrointestinal motility are also summa-
rized in Figure 6. Similarly to CCK-OP, the inhi-
bitory effect can also be triggered by cerulein 
confirming the involvement of the same or similar 
evoking mechanisms [9, 52].  
 CCK exhibits high affinity to both CCK 
receptors, CCK-1 and CCK-2 [2]. CCK engages 
CCK-1 receptor acting centrally on gastric motility 
in sheep [53]. While in ovine omasum, CCK-1 
receptor mediates the action of CCK, in the 
abomasal antrum, CCK-1 receptor antagonist did 
not alter the myoelectrical activity [54, 55]. It is  
thus likely that CCK action in antrum involves 
CCK-2 receptor and is local. This receptor can be 
present in antrum since pentagastrin, acting 
principally via CCK-2 receptor, inhibited antral 
motility in sheep and also in calves [56, 57, see also 
2]. However, it remains unclear whether CCK acted 
as the gut hormone and/or as neuromodulator. 
 In the small intestine, Pi used at the lower 
dose, evoked stimulatory effect, i.e. the premature 
phase 3, which arrived during short inhibitory 
period. This finding was also reported in sheep 
earlier [58]. Since Pi used at the smaller dose 
evoked the premature phase 3 only in some of the 
animals studied, it seems likely that its action via M1 
cholinergic receptor subtype is not entirely specific 
comparing with the actions of another selective 
anticholinergic drug, telenzepine [59-61]. The 
action of the smaller dose of Pi upon the MMC was 
stimulatory, but Pi at the higher dose and other 
anticholinergics inhibited the MMC in sheep and in 
other species including dog that was reported also 
by others [26, 27, 62, 63]. Both CCK and cerulein 
inhibited phase 3 and the whole MMC pattern in 
sheep and similar effect was observed in other 
species like dog in response to CCK administration 
[7, 10, 11,15]. The CCK peptide, applied even at the 
smallest dose after Pi, converted the premature 
phase 3 to rebound excitation. Both the mechanism 
and physiological meaning of this event are 
unknown. After At, Hx and the higher dose of Pi 
given alone, the rebound excitation was observed 
and also described earlier [32, 64]. When CCK 
peptide administration was followed by the 
cholinergic blockade, no rebound excitation was 
observed. Thus, even the small doses of the 
hormone can prevent undesired (stimulatory) 
actions of atropine when used, for example, during 
the intestinal surgery. Since the rebound excitation 
was regularly evoked during cholinergic blockade, it 
appears that the non-adrenergic non-cholinergic 
(NANC) stimulatory neurons underlie its triggering 
mechanism. In the course of the cholinergic 
blockade, the vagus-dependent inhibition may be 
alternated by the stimulation via vagal efferent 
NANC nerves or by other NANC neurons located in 
the enteric nervous system [65, 66]. Therefore, CCK 
might be able to exert central, but also peripheral 
neuronal stimulatory action upon the gastrointestinal 
tract when the cholinergic receptors are blocked. 
Stimulatory effect of CCK on duodenal motility in 
sheep is also consistent with the observations in 
other ruminant species like calves, in which the 
CCK receptor antagonist, tarazepide, depressed the 
duodenal myoelectrical activity [67]. This also 
concerns the dog, cat and guinea pig [41, 68-70]. It 
was found in the present study that CCK evokes 
biphasic or other inconsistent effects upon the ovine 
small bowel motility what was also observed 
previously in the rat and sheep [13, 44, 49, 71, 72]. 
In man, the results are also contradictory. While the 
in vivo study revealed the inhibitory influence of 
CCK-8 on duodenal motility, administration of 
CCK antagonist, loxiglumide, decreased the total 
number of duodenal contractions [30, 43]. In the 
jejunum, CCK is stimulatory in man, dog and rat 
[29, 73, 74]. Stimulatory effect could be exerted    
by direct action of CCK on the small intestinal 
smooth muscle. It was found that during luminal 
perfusion of the small bowel by decanoic acid, the 
CCK-releasing factor, the segmental-type of motor 
activity was induced [75]. When, during in vitro 
study, CCK was applied, it evoked the ejective 
pattern [76]. After CCK, jejunal segment ejected 
fluid bidirectionally, thus the motility pattern 
evoked by CCK exhibited rather stationary charac-
ter. After the cholinergic blockade, stimulatory 
effect of CCK in the small bowel was greatly 
reduced as compared with the experiments engaging 
CCK alone, what was observed both in the present 
and previous studies [11, 13].  
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 The highest dose of CCK peptide, preceded 
by Hx administration, produced considerably longer 
spike burst inhibition than Hx given alone. This 
suggests that the efficient cooperation between CCK 
and nicotinic cholinergic receptors exists in the gut. 
Since duration of the spike burst inhibition in the 
duodeno-jejunum after combined nicotinic-musca-
rinic blockade followed by CCK administration was 
the longest, the effects might be additive, at least     
in part. It has been established that the nicotinic 
receptors are located in the intramural ganglia of the 
gastrointestinal tract while the muscarinic receptors 
are located more distally, mainly on the smooth 
muscle cells [66]. Therefore, the muscarinic 
cholinergic blockade inhibited this regulatory 
pathway although the nicotinic blockade was more 
effcient since it could block also the non-cholinergic 
stimulatory neurons. The concept of command 
(cholinergic) neurons can illustrate this phenomenon 
further [66].  
 It was found herein that cholinergic blockade 
delayed the appearance of phase 3 of the MMC in 
the small bowel. First phase 3 that arrived 
afterwards was ectopic and originated from the 
jejunum. These effects were also earlier described in 
sheep [63, 64]. The cholinergic blockade is more 
efficient than vagotomy in the MMC inhibition     
[22, 77, 78]. CCK is known to exert similar       
effect, not only in sheep [11, 15]. When CCK was 
administered after cholinergic blockade, the 
inhibition of phase 3 of the MMC was prolonged. 
Therefore, in the small bowel CCK amplified the 
effect evoked by cholinergic blockade and the 
question arises whether this effect is additive or 
synergistic, at least in part. Duration of the 
inhibitory period was related to the CCK dose, type 
of cholinergic blockade and region examined. It  
was reported that CCK and acetylcholine potentiate 
mutually their effects both in the stomach and          
in small bowel [3, 79]. When CCK, given under 
cholinergic blockade inhibited the gastrointestinal 
motility, especially of phase 3 of the MMC, its 
action was rather independent of the direct 
acetylcholine influences. It cannot negate the 
presence of cooperation between cholinergic and 
CCK-related mechanisms in the control of gastro-
intestinal motility, however. In monogastrics, CCK 
may inhibit contractions in the duodenum acting 
simultaneously via CCK-1 and CCK-2 receptors 
[18]. It is uncertain whether the same may also 
occur in sheep. It seems likely that the long 
inhibition of phase 3 in the duodenal bulb, observed 
in the present study, occurred because phase 3 in the 
duodenal bulb of sheep is often absent or reduced. 
This was also observed previously [80]. The normal 
(non-ectopic) phase 3 of the MMC originates in 
ewes most frequently from the duodenum [81]. The 
duodenal bulb represents the region distinct from 
the remaining part of the duodenum in sheep [80, 
82]. When in sheep, CCK was given alone, it 
inhibited phase 3 of the MMC for the period shorter 
than that after the combination of CCK with the 
anticholinergic drug [63]. First phase 3 of the MMC 
that arrived following CCK, administered after 
cholinergic blockade, was also ectopic (it started 
from the jejunum). Therefore, the CCK-dependent 
inhibitory mechanisms may cooperate with 
cholinergic mechanisms, perhaps also during partial 
cholinergic blockade. Duration of phase 3 inhibition 
in the jejunum was shorter than that in the 
duodenum. Most pronounced effects were observed 
in the jejunum when application of the highest dose 
of CCK peptide was preceded by nicotinic or 
nicotinic-muscarinic blockade. Thus the effect of 
CCK upon the MMC appears to be evoked 
principally via CCK receptors located within the 
enteric nervous system (both CCK 1 and CCK 2 
receptors, see [2]), possibly in the cooperation with 
other (maybe central) neurons. The direct action of 
CCK on the small intestinal smooth muscle also 
cannot be excluded although it appears more 
feasible in the control of the spike bursts than in the 
control of the MMC. CCK can be released from I 
cells located in the duodenum and jejunum [1]. In 
ruminants, presence of I cells in the small bowel is 
questionable although CCK can be released from 
this region as CCK-OP [83]. During the cholinergic 
blockade, circulating CCK was probably unable to 
act via the central nervous system. It was reported 
that CCK is not able to cross the blood-brain barrier 
[25] thus it seems likely that peripheral CCK cannot 
act centrally. Whether this is really true or not in 
various animal species is not known since it was 
demonstrated in rats that peripherally administered 
CCK acted on the brain stem neurons [84]. 
However, it has been recognized that CCK, most 
probably released from the peripheral neurons 
and/or from the I cells, can evoke the discharge of 
45 | Romański   Cholinergic system and CCK in ovine digestive motility 
European Journal of Biological Research 2017; 7 (1): 31-49 
 
vagal neurons acting through CCK-2 receptors 
located on vagal afferents, while both CCK 
receptors are present in vagus nerve [85]. 
Stimulation of vagal afferents enhances neuronal 
transmission in the nucleus of the solitary tract, 
activates central CCK-1 receptor pathway and 
possibly also acts in other centers of the brain. 
These actions may disrupt the MMC [86]. It was 
also reported that capsaicin affected CCK action on 
gastrointestinal motility in rats that confirms further 
that this mechanism exists [72, 87]. Therefore, 
peripheral CCK may act centrally omitting the 
blood-brain barrier at least in some species (see 
Figure 6).  
 The inhibition of the MR in the duodenal bulb 
was longer than in the duodenum suggesting that the 
latter region represents the main site of MR 
initiation. Although the MR undergoes cholinergic 
influences what was found in this and previous 
studies [23, 28], almost nothing is known as to the 
localization and contribution of the cholinergic 
receptor subtypes involved in the control of the 
pattern. At given intracerebroventricularly in rats 
remained without effect upon the MR evoked 
centrally by naloxone [88]. Thus, the character of 
central control of the MR remains unclear. When 
CCK peptide injection followed the nicotinic 
blockade, the highest dose of CCK-OP was the most 
effective in the MR inhibition observed in the 
duodeno-jejunum. Cerulein often exerted more 
pronounced effect in the jejunum than in the 
duodenum. These differences between the effects 
evoked by both CCK peptides suggest that the 
mechanism of action of these CCK peptides in the 
gut may be similar, but not be the same. Presented 
results indicate that CCK, exerting its action     
under cholinergic blockade, is able to inhibit the 
MR appearance while the nicotinic blockade is  
more efficient than the muscarinic blockade (see 
Figure 7). It seems likely that the mechanisms 
controlling the MR in the small bowel can be 
similar to those controlling the arrival of the 
spontaneous spike bursts. 
 Both lower doses of CCK-OP used in the 
study were physiological. The highest dose also 
appeared to remain within the physiological range, 
perhaps at its upper border [39]. When CCK exerts 
the inhibitory action on the gastrointestinal motility 
via neuronal pathway, the greater dose of exogenous 
hormone may be required. Therefore, the highest 
dose of CCK could be treated as the physiological 
one. This may also depend upon the site of CCK 
action. When CCK acts as a gut hormone its 
physiological dose can be greater than when it acts 
as a neuromodulator. In sheep it is an unexplored 
question while it appears that both these pathways 
can be taken into account. Cerulein doses used in 
this study, i.e. 20 times lower than that of CCK-OP, 
appeared to be relevant to the doses of CCK-OP, 
although it was suggested that cerulein is only 8-15 
times times stronger than CCK-OP [see 14]. The 
long inhibition of phase 3 of the MMC by combined 
actions of both the anticholinergic drugs and CCK 
may result also from the cooperation with other 
regulators like gastrin and somatostatin acting 
centrally or peripherally [19, 89, 90]. Both these 
hormones inhibit the arrival of phase 3 of the MMC 
[56]. The release of somatostatin from the upper 
gastrointestinal segments is possible in this 
situation, since it may be independent of the 
cholinergic system. This view is based upon the 
observation of Bell et al. [4] that in the calf 
somatostatin secretion was not blocked by 
vagotomy. Furthermore, the cooperation of CCK 
with other inhibitory regulators as opioids and with 
some other, like secretin, glucagon, VIP and GIP 
cannot be excluded [79, 91].  
 
5. CONCLUSIONS 
 
 It is concluded that in sheep:  
1) cholinergic system modulates CCK action upon 
the gastro-intestinal motility,  
2) inhibitory actions of CCK upon the gastro-
intestinal motility, observed after cholinergic 
blockade, were dose-dependent,  
3) CCK, acting under cholinergic blockade, prevents 
the arrival of normal and premature phase 3, 
‘minute rhythm and rebound excitation in the gut,  
4) cooperation between the cholinergic system and 
CCK, regarding the inhibition of the gastrointestinal 
motility, is most efficient when the nicotinic 
receptors are involved,  
5) following the application of cholinergic blockade 
the effects of cerulein upon the gastrointestinal 
motility were comparable with those of CCK-OP,  
6) mechanism of pirenzepine action on gastro-
intestinal motility is dose-related,  
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7) the question whether CCK acts as a hormone or 
as neuromodulator still remains unclear. 
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